With 1.67 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.27 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $8.68 whereas the lowest price it dropped to was $8.33. The 52-week range on AUPH shows that it touched its highest point at $10.67 and its lowest point at $4.71 during that stretch. It currently has a 1-year price target of $10.47. Beta for the stock currently stands at 1.24.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AUPH was down-trending over the past week, with a drop of -8.91%, but this was down by -3.90% over a month. Three-month performance surged to 17.70% while six-month performance rose 48.85%. The stock gained 2.07% in the past year, while it has lost -6.68% so far this year. A look at the trailing 12-month EPS for AUPH yields -0.16 with Next year EPS estimates of 0.57. For the next quarter, that number is 0.02. This implies an EPS growth rate of 104.81% for this year and 2100.00% for next year.
Float and Shares Shorts:
At present, 143.11 million AUPH shares are outstanding with a float of 128.78 million shares on hand for trading. On 2024-12-13, short shares totaled 5.53 million, which was 385.99998 higher than short shares on 1731628800. In addition to Mr. Peter S. Greenleaf M.B.A. as the firm’s CEO & Director, Mr. Joseph M. Miller CPA serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.42648998 of AUPH’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, AUPH reported revenue of $67771000.0 and operating income of $11748000.0. The EBITDA in the recently reported quarter was $20908000.0 and diluted EPS was $0.1.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AUPH since 3 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With AUPH analysts setting a high price target of 13.0 and a low target of 8.0, the average target price over the next 12 months is 10.83571. Based on these targets, AUPH could surge 55.13% to reach the target high and fall by -4.53% to reach the target low. Reaching the average price target will result in a growth of 29.3% from current levels.
Analysts have provided yearly estimates in a range of $0.06381818 being high and $0.00236364 being low. For AUPH, this leads to a yearly average estimate of $0.026.
